Abbott Laboratories (ABT) Stock Price, Fundamentals & Analysis

What ABT does

Abbott Laboratories (ABT) discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for conditions such as pancreatic exocrine insufficiency, irritable bowel syndrome, and hormone replacement therapy, and also provides products like clarithromycin, influenza vaccine, and colon-regulating therapies. Abbott Laboratories (ABT) is part of the S&P 500 and operates in the Medical Devices industry within the broader Healthcare sector.

Key numbers explained

• The current price is 103.49 USD, down 0.19% today.
• The trailing P/E ratio of 33.5 shows how much investors pay per dollar of recent earnings; the forward P/E ratio of 17.1 uses expected future earnings and is typically read as a more optimistic valuation gauge.
• The dividend yield of 2.43% tells you the annual dividend as a percentage of the share price; the ex-dividend date is Oct 15, 2026, and 79% of trailing earnings are paid out as dividends.
• Beta of 0.59 indicates the stock tends to move less than the overall market.
• The 52-week range of 81.97 – 136.83 shows the lowest and highest traded prices in the past year; the price is down 22.6% from a year ago.
• Revenue of 46.58 mld. USD with 13% year-over-year growth shows the top-line scale and expansion rate.
• Profit margin of 11.6% and operating margin of 14.7% measure how much of each revenue dollar turns into net profit and operating profit, respectively.
• Return on equity of 10.6% indicates how effectively the company generates profit from shareholders' equity.

Recent news

Recent headlines highlight Abbott's digital health strategy and a formula settlement, which are being discussed as potential factors in the investment case. Other articles frame Abbott Laboratories (ABT) as a trending stock and note its partnership with Berry Street to expand personalized nutrition support. One headline benchmarks Abbott alongside peers such as Labcorp (LH), Stryker Corporation (SYK), and Veeva Systems (VEEV) in the context of therapeutic drug monitoring and market share.

What to watch

Investors typically monitor earnings reports, with the next one scheduled for Oct 14, 2026, for updates on revenue and margin trends. The balance between dividend payout and reinvestment, reflected in the 79% earnings payout ratio, can influence long-term shareholder returns. Broader factors include regulatory developments in Medical Devices, pricing pressure in Healthcare, and currency movements affecting international sales. Comparing Abbott Laboratories (ABT) with peers such as Pfizer (PFE), DaVita (DVA), and Intuitive Surgical (ISRG) can provide context on sector dynamics.